

PART I

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2012

Rs. in Lakhs

Particulars	Stand alone						Consolidated					
	Three months ended		Six months ended		Year Ended	Three months ended		Six months ended		Year Ended		
	30.09.2012	30.06.2012	30.09.2011	30.09.2012		30.09.2011	31.03.2012	30.09.2012	30.09.2011		31.03.2012	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited		
1 Income from operations												
(a) Net sales/income from operations (Net of excise duty)	137,248	111,256	93,344	248,504	195,173	420,461	148,105	119,744	105,105	267,849	211,607	455,056
(b) Other operating income	1,879	1,697	2,425	3,576	3,610	7,684	1,939	1,697	2,425	3,636	3,610	7,684
Total income from operations (net)	139,127	112,953	95,769	252,080	198,783	428,145	150,044	121,441	107,530	271,485	215,217	462,740
2 Expenses												
(a) Cost of material consumed	80,547	66,172	57,763	146,719	112,618	239,329	75,052	56,835	52,245	131,887	104,608	222,551
(b) Purchase of stock-in-trade	1,502	2,407	316	3,909	443	3,552	11,995	13,657	7,338	25,652	10,099	30,030
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,684)	(5,948)	(1,044)	(8,632)	3,292	8,987	(11,396)	(5,754)	355	(17,150)	2,562	(605)
(d) Employee benefits expense	10,809	10,212	9,200	21,021	17,907	36,410	16,703	15,427	13,268	32,130	25,585	53,568
(e) Depreciation and amortisation expense	4,213	4,104	3,436	8,317	6,855	14,294	5,983	5,884	4,622	11,867	9,139	20,053
(f) Provision for decline in the value of long-term investment	1,800	-	-	1,800	-	2,687	-	-	-	-	-	-
(g) Other expenses	23,431	21,574	18,987	45,005	36,948	77,681	32,662	27,301	22,861	59,963	44,507	96,183
Total expenses	119,618	98,521	88,658	218,139	178,063	382,940	130,999	113,350	100,689	244,349	196,500	421,780
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	19,509	14,432	7,111	33,941	20,720	45,205	19,045	8,091	6,841	27,136	18,717	40,960
4 Other Income	622	108	219	730	865	1,906	659	222	626	881	1,355	2,470
5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	20,131	14,540	7,330	34,671	21,585	47,111	19,704	8,313	7,467	28,017	20,072	43,430
6 Finance costs (refer note 7)	2,999	3,030	1,845	6,029	3,567	9,311	3,350	3,311	2,099	6,661	3,991	10,278
7 Foreign exchange (Gain)/Loss (refer note 7)	(12,485)	19,325	14,938	6,840	14,570	19,596	(11,767)	20,645	18,542	8,878	18,224	22,330
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	29,617	(7,815)	(9,453)	21,802	3,448	18,204	28,121	(15,643)	(13,174)	12,478	(2,143)	10,822
9 Exceptional item	-	-	-	-	31,986	31,986	12	-	-	12	31,986	32,118
10 Profit/(Loss) from ordinary activities before tax (8-9)	29,617	(7,815)	(9,453)	21,802	(28,538)	(13,782)	28,109	(15,643)	(13,174)	12,466	(34,129)	(21,296)
11 Tax expense/(credit)	5,816	(2,831)	(5,265)	2,985	(14,192)	(9,521)	5,913	(2,740)	(5,155)	3,173	(13,831)	(8,881)
12 Net Profit/(Loss) for the period (10-11)	23,801	(4,984)	(4,188)	18,817	(14,346)	(4,261)	22,196	(12,903)	(8,019)	9,293	(20,298)	(12,415)
13 Minority Interest	-	-	-	-	-	-	(39)	(12)	(3)	(51)	(3)	(64)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	23,801	(4,984)	(4,188)	18,817	(14,346)	(4,261)	22,235	(12,891)	(8,016)	9,344	(20,295)	(12,351)
15 Paid-up Equity Share Capital (Face value Re. 1 per Share)	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911
16 Reserves excluding Revaluation Reserve	8,17	(1,71)	(1,44)	6,46	(4,93)	(1,46)	7,64	(4,43)	(2,75)	3,21	(6,97)	(4,24)
17 Earnings per share of Rs.1/- each (not annualised)												
(a) Basic	8.17	(1.71)	(1.44)	6.46	(4.93)	(1.46)	7.64	(4.43)	(2.75)	3.21	(6.97)	(4.24)
(a) Diluted	8.17	(1.71)	(1.44)	6.46	(4.93)	(1.46)	7.64	(4.43)	(2.75)	3.21	(6.97)	(4.24)



28/2

PART II

SELECT INFORMATION FOR THE QUARTER & HALF YEAR ENDED 30.09.2012

Particulars	Three months ended			Six months ended		Year Ended 31.03.2012
	30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	
A						
1 PARTICULARS OF SHAREHOLDING						
Public Shareholding	131,708,307	131,708,307	132,860,775	131,708,307	132,860,775	131,708,307
- Number of Shares	45.24	45.24	45.64	45.24	45.64	45.24
- Percentage of Shareholding						
2 Promoters and promoter group Shareholding:						
a) Pledged/Encumbered	34,300,902	36,686,605	22,738,605	34,300,902	22,738,605	35,523,605
- Number of Shares	21.52	23.01	14.37	21.52	14.37	22.28
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	11.78	12.60	7.81	11.78	7.81	12.20
- Percentage of Shares (as a % of the total share capital of the company)	125,112,081	122,726,378	135,521,910	125,112,081	135,521,910	123,889,378
b) Non-encumbered	78.48	76.99	85.63	78.48	85.63	77.72
- Number of Shares	42.98	42.16	46.55	42.98	46.55	42.56
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)						
- Percentage of Shares (as a % of the total share capital of the company)						

Particulars	Three months ended	
	30.09.2012	30.09.2011
B INVESTOR COMPLAINTS		
Pending at the beginning of the quarter	Nil	Nil
Received during the quarter	48	48
Disposed of during the quarter	48	Nil
Remaining unresolved at the end of the quarter	Nil	Nil

28 ✓



NOTES:

- 1 The above unaudited financial results as reviewed by the Audit Committee and has been approved by the Board at its meeting held on November 09, 2012. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- 2 The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- 3 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- 4 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 5 Income from operations of standalone for the current quarter includes exports of Rs. 104,778 lakhs (Quarter ended September 30, 2011: Rs. 69,654 lakhs).
- 6 Net sales for the current quarter include dossier income in standalone of Rs. 428 lakhs (Quarter ended September 30, 2011: Rs. 599 lakhs) and in consolidated of Rs. 1166 lakhs (Quarter ended September 30, 2011: Rs. 1,531 lakhs).
- 7 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of 'AS 16' on Borrowing costs
- 8 During the quarter, the Company has incorporated a new step down subsidiary viz., Auro Health, LLC in USA.
- 9 During the quarter, Aurobindo Pharma Hungary Kft was liquidated and ceased to be a step down subsidiary.
- 10 The Company is under process of approval of managerial remuneration from Central Government amounting to Rs. 250.86 lakhs paid in previous year beyond the limits prescribed under the Companies Act, 1956.
- 11 The results for the quarter in this statement have been reported in format recommended as per the SEBI circular dated April 16, 2012. Accordingly all other periods have also been restated to conform with the current period presentation.

	Three months ended				Six months ended		Year Ended
	30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012	
	4,669	4,776	8,071	9,445	8,071	17,447	

Place: Hyderabad
Date: November 9, 2012



www.aurobindo.com

By Order of the Board
N.G. Kunderajan
Managing Director

Statement of Assets and Liabilities

Rs. In lakhs

Particulars	Stand alone		Consolidated	
	As At 30.09.2012 Unaudited	As At 31.03.2012 Audited	As At 30.09.2012 Unaudited	As At 31.03.2012 Audited
A				
EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share capital	2,911	2,911	2,911	2,911
(b) Reserves and surplus	265,222	246,406	241,650	231,054
	268,133	249,317	244,561	233,965
Sub-total - Shareholders' funds				
2 Share application money pending allotment	-	-	-	-
3 Minority interest	-	-	1,135	1,021
4 Non-current liabilities				
(a) Long-term borrowings	101,910	83,374	113,517	96,463
(b) Deferred tax liabilities (net)	3,309	379	3,314	384
(c) Long-term provisions	875	412	904	424
Sub-total - Non-current liabilities	106,094	84,165	117,735	97,271
5 Current liabilities				
(a) Short-term borrowings	169,638	160,821	176,258	160,821
(b) Trade payables	80,917	58,486	95,256	66,014
(c) Other current liabilities	19,053	40,578	37,070	58,034
(d) Short-term provisions	6,285	5,755	7,386	6,636
Sub-total - Current liabilities	275,893	265,640	315,970	291,505
TOTAL - EQUITY AND LIABILITIES	650,120	599,122	679,401	623,762
B				
ASSETS				
1 Non-current assets				
(a) Fixed assets	219,807	218,483	280,788	278,593
(b) Goodwill on consolidation	-	-	5,454	5,414
(c) Non-current investments	67,837	61,032	1,986	1,986
(d) Deferred tax assets (net)	-	-	577	542
(e) Long-term loans and advances	21,455	17,849	14,651	10,812
(f) Other non-current assets	12	12	12	12
Sub-total - Non-current assets	309,111	297,376	303,468	297,359
2 Current assets				
(a) Current investments	4	1,868	4	1,868
(b) Inventories	144,563	121,928	185,782	154,555
(c) Trade receivables	150,132	142,628	128,014	123,996
(d) Cash and cash equivalents	11,510	1,401	19,733	7,086
(e) Short-term loans and advances	27,032	26,248	34,788	31,485
(f) Other current assets	7,768	7,675	7,612	7,413
Sub-total - Current assets	341,009	301,746	375,933	326,403
TOTAL - ASSETS	650,120	599,122	679,401	623,762

